IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.
Analysts expect the Westbrook, Maine-based company to report quarterly earnings at $3.14 per share, up from $2.80 per share in the year-ago period. The consensus estimate for IDEXX Laboratories' quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier, according to data from Benzinga Pro.
On Aug. 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.
Shares of IDEXX Laboratories rose 0.2% to close at $629.51 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- Stifel analyst Jonathan Block upgraded the stock from Hold to Buy and raised the price target from $640 to $700 on Oct. 31, 2025. This analyst has an accuracy rate of 72%.
- UBS analyst Andrea Alfonso initiated coverage on the stock with a Neutral rating and a price target of $720 on Oct. 1, 2025. This analyst has an accuracy rate of 78%.
- Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 on Aug. 15, 2025. This analyst has an accuracy rate of 73%.
- Piper Sandler analyst David Westenberg maintained a Neutral rating and increased the price target from $510 to $700 on Aug. 11, 2025. This analyst has an accuracy rate of 73%.
- JP Morgan analyst Chris Scott maintained an Overweight rating and raised the price target from $550 to $675 on Aug. 4, 2025. This analyst has an accuracy rate of 62%
Considering buying IDXX stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
